31.10.2012 Views

Chitosan Loaded Mucoadhesive Microspheres of Gliclazide - Journal

Chitosan Loaded Mucoadhesive Microspheres of Gliclazide - Journal

Chitosan Loaded Mucoadhesive Microspheres of Gliclazide - Journal

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Prakash Rao B et al./ Formulation and Evaluation <strong>of</strong> <strong>Mucoadhesive</strong> Buccal Drug Delivery System <strong>of</strong> Metoprolol Tartrate by Using Central Composite Design<br />

Higuchi Release Model<br />

To study the Higuchi release model the release rate data are<br />

fitted into the following equation:<br />

½<br />

Q = K H t (4)<br />

Where, 'Q' is the fraction <strong>of</strong> drug release, 'KH' is the release<br />

rate constant and't' is the release time. The graph is plotted %<br />

CDR verses square root <strong>of</strong> time.<br />

Korsmeyer and Peppas Kinetics<br />

To study the Korsmeyer and Peppas release kinetics the<br />

release rate data are fitted in to following equation:<br />

n<br />

Mt/M∞ = K KP t (5)<br />

Where, Mt/M∞ is the fraction <strong>of</strong> drug release, 'K ' is the<br />

KP<br />

release rate constant and 't' is the release time and 'n' is the<br />

diffusion exponent related to mechanism <strong>of</strong> drug release. The<br />

graph is plotted log %CDR verses log time.<br />

Fourier Transform Infrared Spectroscopy (FT-IR)<br />

IR spectroscopy was carried out for the following A) Pure<br />

drug, B) Drug + carbopol C) Drug + HPC using Shimadzu<br />

FTIR model 8700by taking KBr disc. The instrument was<br />

operated under dry air purge and the scans were collected at<br />

-1<br />

scanning speed <strong>of</strong> 2mm\sec with resolution <strong>of</strong> 4cm over the<br />

-1 18<br />

region <strong>of</strong> 4000-400 cm .<br />

Differential Thermal Analysis (DTA)<br />

The sample <strong>of</strong> MT, carbopol, HPC and their binary mixtures<br />

were weighed and sealed in 40 ml aluminum crucibles with a<br />

pierced aluminum lid. The analyses were performed under<br />

nitrogen (nitrogen flow rate 50 ml/min) in order to eliminate<br />

oxidative and pyrrolytic effects at a standard heating rate <strong>of</strong><br />

15ºC/minute over a temperature range <strong>of</strong> 30ºC - 300ºC using<br />

a Mettler-Toledo star system.<br />

Stability studies<br />

An accelerated stability study was carried out according to<br />

ICH guidelines. The optimized formulation was kept in 2 ml<br />

0<br />

<strong>of</strong> glass vial and closed. The vials were kept at 40 ± 2 C / 75<br />

RH ± 5% RH for six months in a dessicator. After end <strong>of</strong><br />

every month, tablets were evaluated for bioadhesive strength<br />

and drug content.<br />

RESULTS AND DISCUSSION<br />

Development <strong>of</strong> Formulations<br />

Evaluation <strong>of</strong> Tablets<br />

The average thickness <strong>of</strong> the all buccal tablets ranges from<br />

2.12 to 3.25 mm. The value <strong>of</strong> percentage variation in weight<br />

and friability were found to be with in the limit <strong>of</strong><br />

149<br />

conventional oral tablets stated in the Indian pharmacopeia.<br />

Hardness <strong>of</strong> all buccal tablets was higher because <strong>of</strong> the<br />

carbopol. In all the formulations, the assay for drug content<br />

was found to be in the range from 47.56 mg to 49.65 mg.<br />

In-vitro drug release study after 8 hour<br />

Total amount <strong>of</strong> metoprolol tartrate released from all<br />

formulations ranges from 60.45% to 87.90% in 8 hours (Table<br />

3). Decreased rate <strong>of</strong> drug release was observed with increase<br />

<strong>of</strong> the concentration <strong>of</strong> polymers. (Fig. 2-4) illustrates the<br />

release pr<strong>of</strong>ile <strong>of</strong> all formulations. When the tablets contact<br />

Fig. 2: In-vitro drug release pr<strong>of</strong>iles <strong>of</strong> formulation F-1 to F-5<br />

Fig. 3: In-vitro drug release pr<strong>of</strong>iles <strong>of</strong> formulation F-6 to F-9<br />

Fig. 4: In- vitro drug release pr<strong>of</strong>iles <strong>of</strong> formulation F-10 to F-13<br />

RJPS, Jul - Sep, 2011/ Vol 1/ Issue 2

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!